Published May 21, 2010 | Version v1
Journal article Metadata-only

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer

Creators

  • 1. Institut Curie, Department of Translational Research, 26 rue d'Ulm, 75248 Paris, Cedex 05 (France)
  • 2. Institut Curie, Department of Surgery, 26 rue d'Ulm, 75248 Paris, Cedex 05 (France)
  • 3. Institut Curie, Department of Medical Oncology, 26 rue d'Ulm, 75248 Paris, Cedex 05 (France)
  • 4. Institut Curie, Department of Pathology, 26 rue d'Ulm, 75248 Paris, Cedex 05 (France)
  • 5. CNRS, UMR144, 26 rue d'Ulm, 75248 Paris, Cedex 05 (France)
  • 6. Institut Curie, Research Unit, 26 rue d'Ulm, 75248 Paris, Cedex 05 (France)
  • 7. INSERM, U830, 26 rue d'Ulm, 75248 Paris, Cedex 05 (France)

Description

The distinction between primary and secondary ovarian tumors may be challenging for pathologists. The purpose of the present work was to develop genomic and transcriptomic tools to further refine the pathological diagnosis of ovarian tumors after a previous history of breast cancer. Sixteen paired breast-ovary tumors from patients with a former diagnosis of breast cancer were collected. The genomic profiles of paired tumors were analyzed using the Affymetrix GeneChip® Mapping 50 K Xba Array or Genome-Wide Human SNP Array 6.0 (for one pair), and the data were normalized with ITALICS (ITerative and Alternative normaLIzation and Copy number calling for affymetrix Snp arrays) algorithm or Partek Genomic Suite, respectively. The transcriptome of paired samples was analyzed using Affymetrix GeneChip® Human Genome U133 Plus 2.0 Arrays, and the data were normalized with gc-Robust Multi-array Average (gcRMA) algorithm. A hierarchical clustering of these samples was performed, combined with a dataset of well-identified primary and secondary ovarian tumors. In 12 of the 16 paired tumors analyzed, the comparison of genomic profiles confirmed the pathological diagnosis of primary ovarian tumor (n = 5) or metastasis of breast cancer (n = 7). Among four cases with uncertain pathological diagnosis, genomic profiles were clearly distinct between the ovarian and breast tumors in two pairs, thus indicating primary ovarian carcinomas, and showed common patterns in the two others, indicating metastases from breast cancer. In all pairs, the result of the transcriptomic analysis was concordant with that of the genomic analysis. In patients with ovarian carcinoma and a previous history of breast cancer, SNP array analysis can be used to distinguish primary and secondary ovarian tumors. Transcriptomic analysis may be used when primary breast tissue specimen is not available

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-10-222; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891634

Additional details

Identifiers

URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891634;
DOI
10.1186/1471-2407-10-222;

Publishing Information

Journal Title
BMC Cancer (Online)
Journal Volume
10
Journal Page Range
p. 222
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46093311
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ALGORITHMS; CARCINOMAS; DATASETS; DIAGNOSIS; MAMMARY GLANDS; MAPPING; METASTASES; OVARIES; PATIENTS
Descriptors DEC
BODY; DISEASES; DOCUMENT TYPES; FEMALE GENITALS; GLANDS; GONADS; MATHEMATICAL LOGIC; NEOPLASMS; ORGANS

Optional Information

Copyright
Copyright (c)2010 Meyniel et al
Notes
PMCID: PMC2891634; PUBLISHER-ID: 1471-2407-10-222; PMID: 20492709; OAI: oai:pubmedcentral.nih.gov:2891634; licensee BioMed Central Ltd.